Endoscopic sleeve gastroplasty more cost-effective than with semaglutide
An economic evaluation comparing endoscopic sleeve gastroplasty (ESG) with semaglutide for treating class II obesity has suggested ESG is...
Endoscopic sleeve gastroplasty more cost-effective than with semaglutide
Looking forward to IFSO 2024
No association between suicidal, self-injurious thoughts and actions and GLP-1s
Latest findings from the IFSO Global Registry
Tirzepatide associated with a potential targeted effect on visceral fat and liver fat
CMS' semaglutide coverage expansion could save millions of lives
Journal Watch 10/4/2024